# US 2003/0225022 A1 · Suppression of eIF5A1 expression to prevent retinal ganglion cell death in the glaucomatous eye

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225022 A1
- Document ID: US20030225022A1
- Status: Published application
- Kind: A1
- Application number: 10/383,614
- Filed: 2003-03-10
- Published: 2003-12-04
- Earliest claimed: 2001-07-23
- Assignees: Sensco Technologies, Inc.
- Inventors: Catherine Taylor; Dominic Cliche; Elizabeth Margaret Heikkila; Diane Michelle Senchyna; John Gerard Flanagan; John E. Thompson
- Web page: https://patentgrep.com/patent/US20030225022A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIfF5A1.

## Claims

### Claim 1

1) A method for preventing retinal ganglion cell death in a glaucomatous eye, said method comprising suppressing expression of apoptosis-specific eIF5A1 in retinal ganglion cells.

### Claim 2 (depends on 1)

2) The method of claim 1 wherein the suppressing expression of apoptosis-specific eIF5A1 comprises administration of antisense oligonucleotides to said retinal ganglion cells, wherein said antisense oligonucleotides are targeted against human apoptosis-specific eIF5A1.

### Claim 3 (depends on 1)

3) The method of claim 1 wherein said antisense oligonucleotide is SEQ ID NO: 26 or 27.

### Claim 4 (depends on 3)

4) The method of claim 3 wherein said antisense oligonucleotide is SEQ ID NO: 26 or an oligonucleotide that hybridizes under stringent conditions to a sequence complementary to SEQ ID NO: 26.

### Claim 5 (depends on 3)

5) The method of claim 3 wherein said antisense oligonucleotide is SEQ ID NO: 27 or an oligonucleotide that hybridizes under stringent conditions to a sequence complementary to SEQ ID NO: 27.

### Claim 6

6) A method of suppressing expression of apoptosis-specific eIF5A1 in lamina cribosa cells, the method comprising transfecting lamina cribosa cells with antisense oligonucleotides targeted against human apoptosis-specific eIF5A1, wherein said antisense oligonucleotides supress expression of apoptosis-specific eIF5A1 in said cells.

### Claim 7 (depends on 6)

7) The method of claim 6 wherein the lamina cribosa cells are human.

### Claim 8 (depends on 7)

8) The method of claim 7 wherein the antisense oligonucleotide is SEQ ID NO: 26 or an oligonucleotide that hybridizes under stringent conditions to a sequence complementary to SEQ ID NO: 26.

### Claim 9 (depends on 7)

9) The method of claim 7 wherein the antisense oligonucleotide is SEQ ID NO: 27 or an oligonucleotide that hybridizes under stringent conditions to a sequence complementary to SEQ ID NO: 27.

### Claim 10

10) A method of suppressing expression of apoptosis-specific eIF5A1 in astrocyte cells, the method comprising transfecting astrocyte cells with antisense oligonucleotides targeted against human apoptosis-specific eIF5A1, wherein said antisense oligonucleotides supress expression of apoptosis-specific eIF5A1 in said cells.

### Claim 11 (depends on 10)

11) The method of claim 10 wherein said astrocyte cells are human.
